Breaking the cycle of recurrent Clostridium difficile infections

Clinical Microbiology and Infection

Volumn 18, Issue SUPPL.6, 2012, Pages 2-4

  Fitzpatrick, F ^a   Barbut, F ^b,c  

^a HEALTH PROTECTION SURVEILLANCE CENTRE   (Ireland)

^b HÔPITAL SAINT ANTOINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN;

ANTIBIOTIC THERAPY; BLOODSTREAM INFECTION; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; DIAGNOSTIC TEST; DRUG APPROVAL; EDITORIAL; EUROPE; FECES MICROFLORA; HEALTHCARE ASSOCIATED INFECTION; HUMAN; HYGIENE; INCIDENCE; INFECTION RISK; INFECTIOUS DIARRHEA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORBIDITY; MORTALITY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT INFECTION; WASTE MANAGEMENT;

EID: 84868557463     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12043     Document Type: Editorial

References (26)

1. Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect 2012; 18: 5-12.
2. Alcalá L, Martín A, Marín M et al. The undiagnosed cases of Clostridium difficile infection in a whole nation: where is the problem?Clin Microbiol Infect 2012; 18: E204-E213.
3. Vonberg RP, Reichartd C, Behnke M et al. Costs of nosocomial Clostridium difficile-associated diarrhoea. J Hosp Infect 2008; 70: 15-20.
4. Kuijper EJ, Coignard B, Tull P et al. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006; 12: 2-18.
5. Wilcox MH. Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection. Clin Microbiol Infect 2012; 18: 13-20.
6. Crobach MJT, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: data review and recommendations for diagnosing Clostridium difficile infection. Clin Microbiol Infect 2009; 15: 1053-1066.
7. Alcalá L, Marín M, Martín A et al. Laboratory diagnosis of Clostridium difficile infection in Spain: a population-based survey. J Hosp Infect 2011; 79: 13-17.
8. Barbut F, Delmée M, Brazier JS et al. A European survey of diagnostic methods and testing protocols for Clostridium difficile. Clin Microbiol Infect 2003; 9: 989-996.
9. Wilcox MH. Laboratory diagnosis of Clostridium difficile infection: in a state of transition or confusion or both?J Hosp Infect 2011; 79: 1-3.
10. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-431.
11. Bouza E, Dryden M, Mohammed R et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea. Clin Microbiol Infect 2008; 14: S103-S104.
12. Lowy I, Molrine DC, Leav BA et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362: 197-205.
13. Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection?Clin Microbiol Infect 2012; 18: 21-27.
14. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet 2001; 357: 189-193.
15. Do AN, Fridkin SK, Yechouron A et al. Risk factors for early recurrent Clostridium difficile-associated diarrhea. Clin Infect Dis 1998; 26: 954-959.
16. Cohen MB. Clostridium difficile infections: emerging epidemiology and new treatments. J Pediatr Gastroenterol Nutr 2009; 48 (suppl 2): S63-S65.
17. Cornely OA. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?Clin Microbiol Infect 2012; 18: 28-39.
18. Brandt LJ, Aroniadis OC, Mellow M et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 1079-1087.
19. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases: treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2009; 15: 1067-1079.
20. Bauer MP, Notermans DW, van Benthem BHB et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377: 63-73.
21. Huhulescu S, Sagel U, Fiedler A et al. Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile. J Med Microbiol 2011; 60: 1206-1212.
22. Johnson S, Schriever C, Galang M et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44: 846-848.
23. European Medicines Agency. Summary of Product Characteristics for DIFICLIR (fidaxomicin), 5 December 2011; EU/1/11/733/001-004. London, UK: European Medicines Agency.
24. Cornely OA, Crook DW, Esposito R et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12: 281-289.
25. Petrella LA, Sambol SP, Cheknis A et al. Decreased cure rate and increased recurrence rate for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 2012; 55: 351-357.
26. Wilcox MH, Cunniffe JG, Trundle C, Redpath C. Financial burden of hospital-acquired Clostridium difficile infection. J Hosp Infect 1996; 34: 23-30.